Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.

Autor:	Lancet, J. E.1 jeffrey.lancet@moffitt.org, Gojo, I.2, Burton, M.1, Quinn, M.2, Tighe, S. M.3, Kersey, K.4, Zhong, Z.4, Albitar, M. X.5, Bhalla, K.6, Hannah, A. L.4, Baer, M. R.2,3
Zdroj:	Leukemia (08876924). Apr2010, Vol. 24 Issue 4, p699-705. 7p. 3 Charts, 3 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu